nash semaglutide and lanifibranor differentially improves histological Evaluation of long acting GLP1R/GCGR

Early clinical data demonstrate unprecedented reductions in body weight (2024%) alongside substantial HbA1c lowering, highlighting the metabolic advantage of multi-receptor targeting

Shalender Bhasin, the TRAVERSE trial's principal investigator, stated: "Testosterone replacement therapy in middle-aged and older men with hypogonadism and cardiovascular risk did not increase the incidence of major cardiovascular events, but clinicians should still monitor for non-cardiac adverse effects" [7]

Nutraceuticals and supplements in the management of prediabetes and diabetes: Mechanistic and clinical evidence

What dose of retatrutide will be prescribed